Identification of RO4597014, a glucokinase activator studied in the clinic for the treatment of type 2 diabetes

ACS Medicinal Chemistry Letters

Volumn 4, Issue 4, 2013, Pages 414-418

  Qian, Yimin ^a   Corbett, Wendy L ^a   Berthel, Steven J ^a   Choi, Duk Soon ^a   Dvorozniak, Mark T ^a   Geng, Wanping ^b   Gillespie, Paul ^a   Guertin, Kevin R ^a   Haynes, Nancy Ellen ^a   Kester, Robert F ^a   Mennona, Francis A ^a   Moore, David ^a   Racha, Jagdish ^a   Radinov, Roumen ^a   Sarabu, Ramakanth ^a   Scott, Nathan R ^a   Grimsby, Joseph ^a   Mallalieu, Navita L ^a  

^a Hoffmann La Roche ^*  (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Glucokinase activator; lipophilic ligand efficiency; metabolite; redox cycling; type 2 diabetes

Indexed keywords

CYTOCHROME P450 3A4; ENZYME ACTIVATOR; LIGAND; POTASSIUM CHANNEL HERG; RO 4597014; UNCLASSIFIED DRUG;

ARTICLE; DIET; DRUG SAFETY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

MUS;

EID: 84876270016     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400027y     Document Type: Article

References (19)

1. Matschinsky, F. M. Assessing the potential of glucokinase activators in diabetes therapy Nat. Rev. Drug Discovery 2009, 8, 399-416
2. Grimsby, J.; Sarabu, R.; Corbett, W. L.; Haynes, N. E.; Bizzarro, F. T.; Coffey, J. W.; Guertin, K. R.; Hilliard, D. H.; Kester, R. F.; Mahaney, P. E.; Marcus, L.; Qi, L.; Spence, C. L.; Tengi, J.; Magnuson, M. A.; Chu, C. A.; Dvorozniak, M. T.; Matschinsky, F. M.; Grippo, J. F. Allosteric activators of glucokinase: potential role in diabetes therapy Science 2003, 301, 370-373
3. Haynes, N. E.; Corbett, W. L.; Bizzarro, F. T.; Guertin, K. R.; Hilliard, D. W.; Holland, G. W.; Kester, R. F.; Mahaney, P. E.; Qi, L.; Spence, C. L.; Tengi, J.; Dvorozniak, M. T.; Railkar, A.; Matschinsky, F. M.; Grippo, J. F.; Grimsby, J.; Sarabu, R. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2 R)-3-cyclopentyl-2- (4-methanesulfonylphenyl)- N -thiazol-2-yl-propionamide (RO0281675) J. Med. Chem. 2010, 53, 3618-3625
4. McKerrecher, D.; Allen, J. V.; Caulkett, P. W. R.; Donald, C. S.; Fenwick, M. L.; Grange, E.; Johnson, K. M.; Johnstone, C.; Jones, C. D.; Pike, K. G.; Rayner, J. W.; Walker, R. P. Design of a potent, soluble glucokinase activator with excellent in vivo efficacy Bioorg. Med. Chem. Lett. 2006, 16, 2705-2709
5. Waring, M. J.; Johnstone, C.; McKerrecher, D.; Pike, K. G.; Robb, G. Matrix-based multiparameter optimization of glucokinase activators: the discovery of AZD1092 Med. Chem. Commun. 2011, 2, 775-779
6. Waring, M. J.; Clarke, D. S.; Fenwick, M. D.; Godfrey, L.; Groombridge, S. D.; Johnstone, C.; McKerrecher, D.; Pike, K. G.; Rayner, J. W.; Robb, G. R.; Wilson, I. Property based optimization of glucokinase activators: discovery of phase IIb clinical candidate AZD1656 Med. Chem. Commun. 2012, 3, 1077-1081
7. Mao, W.; Ning, M.; Liu, Z.; Zhu, Q.; Leng, Y.; Zhang, A. Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators Bioorg. Med. Chem. 2012, 20, 2982-2991
8. Meininger, G. E.; Scott, R.; Alba, M.; Shentu, Y.; Luo, E.; Amin, H.; Davies, M. J.; Kaufman, K. D.; Goldstein, B. J. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes Diabetes Care 2011, 34, 2560-2566
9. Takahashi, K.; Hashimoto, N.; Nakama, C.; Kamata, K.; Sasaki, K.; Yoshimoto, R.; Ohyama, S.; Hosaka, H.; Maruki, H.; Nagata, Y.; Eiki, J. I.; Nishimura, T. The design and optimization of a series of 2-(pyridin-2-yl)-1 H -benzimidazole compounds as allosteric glucokinase activators Bioorg. Med. Chem. 2009, 17, 7042-7051
10. Nishimura, T.; Iino, T.; Mitsuya, M.; Bamba, M.; Watanabe, H.; Tsukahara, D.; Kamata, K.; Sasaki, K.; Ohyama, S.; Hosaka, H.; Futamura, M.; Nagata, Y.; Eiki, J. I. Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators Bioorg. Med. Chem. Lett. 2009, 19, 1357-1360
11. Bertram, L. S.; Black, D.; Briner, P. H.; Chatfield, R.; Cooke, A.; Fyfe, M. C. T.; Murray, P. J.; Naud, F.; Nawano, M.; Procter, M. J.; Rakipovski, G.; Rasamison, C. M.; Reynet, C.; Schofield, K. L.; Shah, V. K.; Spindler, F.; Taylor, A.; Turton, R.; Williams, G. M.; Wong-Kai-In, P.; Yasuda, K. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)- N -thiazol-2-ylacetamides: discovery of PSN-GK1 J. Med. Chem. 2008, 51, 4340-4345
12. Bebernitz, G. R.; Beaulieu, V.; Dale, B. A.; Deacon, R.; Duttaroy, A.; Gao, J.; Grondine, M. S.; Gupta, R. C.; Kakmak, M.; Kavana, M.; Kirman, L. C.; Liang, J.; Maniara, W. M.; Munshi, S.; Nadkarni, S. S.; Schuster, H. F.; Stams, T.; St. Denny, I.; Taslimi, P. M.; Vash, B.; Caplan, S. L. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes J. Med. Chem. 2009, 52, 6142-6152
13. Pfefferkorn, J. A.; Guzman-Perez, A.; Litchfield, J.; Aiello, R.; Treadway, J. L.; Pettersen, J.; Minich, M. L.; Filipski, K. J.; Jones, C. S.; Tu, M.; Aspnes, G.; Risley, H.; Bian, J.; Stevens, B. D.; Bourassa, P.; D'Aquila, T.; Baker, L.; Barucci, N.; Robertson, A. S.; Bourbonais, F.; Derksen, D. R.; MacDougall, M.; Cabrera, O.; Chen, J.; Lapworth, A. L.; Landro, J. A.; Zavadoski, W. J.; Atkinson, K.; Haddish-Berhane, N.; Tan, B.; Yao, L.; Kosa, R. E.; Varma, M. V.; Feng, B.; Duignan, D. B.; El-Kattan, A.; Murdande, S.; Liu, S.; Ammirati, M.; Knafels, J.; DaSilva-Jardine, P.; Sweet, L.; Liras, S.; Rolph, T. P. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1 H -imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus J. Med. Chem. 2012, 55, 1318-1333
14. Sarabu, R.; Bizzarro, F. T.; Corbett, W. L.; Dvorozniak, M. T.; Geng, W.; Grippo, J. F.; Haynes, N. E.; Hutchings, S.; Garofalo, L.; Guertin, K. R.; Hilliard, D. W.; Kabat, M.; Kester, R. F.; Wang, K.; Liang, Z.; Mahaney, P. E.; Marcus, L.; Matschinsky, F. M.; Moore, D.; Racha, J.; Radinov, R.; Ren, Y.; Qi, L.; Pignatello, M.; Spence, C. L.; Steele, T.; Tengi, J.; Grimsby, J. Discovery of Piragliatin-first glucokinase activator studied in type 2 diabetic patients J. Med. Chem. 2012, 55, 7021-7036
15. Meanwell, N. A. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 2011, 24, 1420-1456
16. Chen, S.; Corbett, W. L.; Guertin, K. R.; Haynes, N.; Kester, R. F.; Mennona, F. A.; Mischke, S. G.; Qian, Y.; Sarabu, R.; Scott, N. R.; Thakkar, K. C. 5-Substituted-Six-Membered Heteroaromatic Glucokinase Activators. U.S. Patent 7,132,425, 2006.
17. Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. Catalytic asymmetric dihydroxylation Chem. Rev. 1994, 94, 2483-2547
18. Berthel, S. J.; Brinkman, J. A.; Hayden, S.; Haynes, N. E.; Kester, R. F.; McDermott, L. A.; Qian, Y.; Sarabu, R.; Scott, N. R.; Tilley, J. W. Pyrrolidinone Glucokinase Activators. U.S. Patent 7,741,327, 2010.
19. Berthel, S. J.; Haynes, N. E.; Kester, R. F.; McDermott, L. A.; Qian, Y.; Sarabu, R.; Scott, N. R.; Tilley, J. W. Pyridazinone Glucokinase Activators. U.S. Patent 8,258,134, 2012.